A Phase 1 interventional study of Rilzabrutinib in Hepatic Function Abnormal and Healthy Volunteers, sponsored by Principia Biopharma, a Sanofi Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-05.
Sponsored by Principia Biopharma, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.
Among the 368 studies in Liver Diseases with a site in United States, this one is the 169th largest by enrollment of the 269 interventional ones that give a count, is one of 17 that started in 2020, is one of 62 in phase 1, and was the 342nd registered.
825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.
Browse Liver Diseases studies →45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:
West Virginia University · Sites in United States
Ages 18+
AusperBio Therapeutics Inc. · Sites in United States, Canada, France and 3 more countries
Ages 18–65
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 6–17
Incyte Corporation · Sites in United States
Ages 18–80
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
368 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 75 · Phase 3 30 · Phase 4 21
First in 1988; this study’s year is marked. 17 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 52 across 522 interventional studies indexed under Liver Diseases.
Median enrollment 48 across the 269 interventional studies, 153 across the 90 observational. Of the 276 that completed or were terminated, 115 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
146 of 368 have an industry lead sponsor. The 10 most frequent:
This study is registered under Principia Biopharma, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Principia Biopharma, a Sanofi Company is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Sanofi has 7 studies filed under Liver Diseases — fewer than ten, so there is no comparison to draw.
21 of the studies in Liver Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04612764Baylor College of MedicineLiver Disease in Urea Cycle Disorders | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT05953337ABK BiomedicalRadioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | 2027-02 |
| NCT05264051University of ChicagoMAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease | 2027-03-01 |
| NCT07746999Corey DeStefanoNorth Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health | 2027-03-15 |
Add all 21 to your calendar (.ics) → With an account.
Among the 368 studies in Liver Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-dose study to assess the effect of mild or moderate Hepatic Impairment (HI) on the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the safety and tolerability of rilzabrutinib in subjects with HI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hepatic Impaired Subjects:
Healthy Subjects:
Subject must be matched for age (within ± 10 years), and sex of the matched subject with hepatic impairment.
--Weight ≥ 50 kg at screening.
Additional inclusion criteria might apply.
Exclusion Criteria:
Hepatic Impaired Subjects:
Healthy Subjects
Additional exclusion criteria might apply.
Subjects with mild Hepatic Impairment (HI)
Drug: Rilzabrutinib
Subjects with moderate Hepatic Impairment (HI)
Drug: Rilzabrutinib
Subjects with normal hepatic function
Drug: Rilzabrutinib
Rilzabrutinib tablet administered orally
Area under the concentration-time curve of total rilzabrutinib in plasma from 0 to t (AUC0-t)
Time frame: Up to 30 hours after rilzabrutinib dosing
Area under the concentration-time curve of total rilzabrutinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)
Time frame: Up to 30 hours after rilzabrutinib dosing
Percent of AUC0-inf extrapolated total rilzabrutinib in plasma (%AUCextrap )
Time frame: Up to 30 hours after rilzabrutinib dosing
Maximum measured concentration of total rilzabrutinib in plasma (Cmax)
Time frame: Up to 30 hours after rilzabrutinib dosing
Time from dosing to maximum measured concentration of total rilzabrutinib in plasma (tmax)
Time frame: Up to 30 hours after rilzabrutinib dosing
Terminal Half-Life of total rilzabrutinib in Plasma (t1/2)
Time frame: Up to 30 hours after rilzabrutinib dosing
Elimination Rate Constant of total rilzabrutinib (Kel)
Time frame: Up to 30 hours after rilzabrutinib dosing
Apparent Total Clearance of rilzabrutinib in the plasma after extra-vascular administration (CL/F)
Time frame: Up to 30 hours after rilzabrutinib dosing
Apparent Volume of Distribution during the Terminal elimination phase after extravascular administration (Vz/F)
Time frame: Up to 30 hours after rilzabrutinib dosing
Fraction of unbound drug ( rilzabrutinib) expressed as percent (%fu)
Time frame: Up to 24 hours after rilzabrutinib dosing
Number of Adverse Events (AE) / Serious Adverse Events (SAE)
Time frame: From date of signed ICF, up to 9 days after rilzabrutinib dosing
Incidence of potentially clinically significant laboratory test, vital signs, and electrocardiogram (ECGs) abnormalities
Time frame: Up to 30 hours after rilzabrutinib dosing
Area under the concentration-time curve of rilzabrutinib metabolites in plasma from 0 to t (AUC0-t)
Time frame: Up to 24 hours after rilzabrutinib dosing
Area under the concentration-time curve of rilzabrutinib metabolites in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)
Time frame: Up to 24 hours after rilzabrutinib dosing
Percent of AUC0-inf extrapolated rilzabrutinib metabolites in plasma (%AUCextrap)
Time frame: Up to 24 hours after rilzabrutinib dosing
Maximum measured concentration of rilzabrutinib metabolites in plasma (Cmax)
Time frame: Up to 24 hours after rilzabrutinib dosing
Time from dosing to maximum measured concentration of rilzabrutinib metabolites in plasma (tmax)
Time frame: Up to 24 hours after rilzabrutinib dosing
Terminal Half-Life of rilzabrutinib metabolites in Plasma (t1/2)
Time frame: Up to 24 hours after rilzabrutinib dosing
Elimination Rate Constant of rilzabrutinib metabolites (Kel)
Time frame: Up to 24 hours after rilzabrutinib dosing
Metabolite-to-parent ratio (MRAUC)
MRAUC is Based on AUC0-t, corrected for Molecular weights (MW). MRAUC = (AUC0-t,M/AUC0-t,P) x (MW,P/MW,M) where M was metabolite and P was parent.
Time frame: Up to 24 hours after rilzabrutinib dosing
Metabolite-to-parent ratio (MRCmax)
MRCmax is based on Cmax, corrected for MW. MRCmax = (Cmax,M/ Cmax,P) x (MW,P/MW,M) where M was metabolite and P was parent.
Time frame: Up to 24 hours after rilzabrutinib dosing
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Nov 2020 to primary completion in Mar 2021, 4 months.
Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 4 months is below that.
Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilzabrutinib
Principia Biopharma, a Sanofi Company →